Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety

被引：0

作者：

Fabi, A. ^{[1
]}

Alesini, D. ^{[1
]}

De laurentiis, M. ^{[2
]}

Valle, E. ^{[3
]}

Santini, D. ^{[4
]}

Cannita, K. ^{[5
]}

Carbognin, L. ^{[6
]}

Ciccarese, M. ^{[7
]}

Arpino, G. ^{[8
]}

Leonardi, V. ^{[9
]}

Montemurro, F. ^{[10
]}

La Verde, N. ^{[11
]}

Generali, D. G. ^{[12
]}

Scandurra, G. ^{[13
]}

Russillo, M. ^{[14
]}

Paris, I. ^{[15
]}

D'Ottavio, A. M. ^{[16
]}

Filippelli, G. ^{[17
]}

Stani, S. ^{[18
]}

Giannarelli, D. ^{[1
]}

Cognetti, F. ^{[1
]}

机构：

[1] Ist Nazl Tumori Regina Elena, Rome, Italy

[2] Fdn Pascale, Ist Nazl Tumori, Naples, Italy

[3] Osped A Businco, Cagliari, Italy

[4] Campus Bio Med, Rome, Italy

[5] Presidio Osped S Salvatore, Laquila, Italy

[6] Azienda Univ Integrata Verona, Verona, Italy

[7] Osped Vito Fazzi, Lecce, Italy

[8] Univ Federico II, Naples, Italy

[9] ARNAS Civ, Palermo, Italy

[10] Fdn Piemonte Oncol, Candiolo, Italy

[11] Osped San Raffaele, Milan, Italy

[12] Ist Osped, Cremona, Italy

[13] Osped Oncol, Catania, Italy

[14] Osped Oncol, Lucca, Italy

[15] Univ Cattolica Sacro Cuore A Gemelli, Rome, Italy

[16] Osped S Giovanni Addolorata, Rome, Italy

[17] Osped S Francesco Paola, Paola, Italy

[18] Osped Santo Spirito, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw337.7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

F07

引用

页数：1

共 50 条

[31] HER2 expression and efficacy of T-DM1
Montemurro, Filippo
BREAST CANCER RESEARCH, 2014, 16 (06):
[32] HER2 expression and efficacy of T-DM1
Filippo Montemurro
Breast Cancer Research, 16
[33] Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan
Wang, Lin-Chien
Kuo, Chun-Nan
Ko, Yu
BREAST JOURNAL, 2020, 26 (10): : 2099 - 2102
[34] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
Jin, Jin
Wang, Bei
Gao, Yuying
Samant, Meghan
Li, Chunze
Song, Chunyan
Swain, Sandra M.
Untch, Michael
Girish, Sandhya
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[35] HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1
Akamatsu, Hiroaki
Mino, Rosa
Mettlen, Marcel
Ye, Dan
Sudhan, Dhivya R.
Lin, Albert
Marin, Arnaldo
Servetto, Alberto
Lee, Kyung-min
Chatterjee, Sumanta
Schmid, Sandra L.
Arteaga, Carlos L.
Hanker, Ariella B.
CANCER RESEARCH, 2020, 80 (16)
[36] Activity of T-DM1 in HER2-positive breast cancer brain metastases
Bartsch, Rupert
Berghoff, Anna S.
Vogl, Ursula
Rudas, Margaretha
Bergen, Elisabeth
Gnant, Michael
Dieckmann, Karin
Pinker, Katja
Bago-Horvath, Zsuzsanna
Galid, Arik
Oehler, Leopold
Zielinksi, Christoph C.
Steger, Guenther G.
Preusser, Matthias
CANCER RESEARCH, 2015, 75
[37] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
Sliwkowski, Mark X.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[38] Activity of T-DM1 in HER2-positive breast cancer brain metastases
Bartsch, R.
Berghoff, A. S.
Rudas, M.
Bergen, E.
Gnant, M.
Dieckmann, K.
Pinker, K.
Zielinski, C. C.
Preusser, M.
Steger, G. G.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S184 - S184
[39] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
Jacot, W.
Pons, E.
Guiu, S.
Levy, C.
Frenel, J-S
Bachelot, T.
D'Hondt, V.
Firmin, N.
Romieu, G.
Thezenas, S.
Dalenc, F.
CANCER RESEARCH, 2016, 76
[40] Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
Zhang, Jing
Li, Jinying
Zhu, Chenjing
Song, Yanlin
Xia, Fan
Ma, Xuelei
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3235 - 3244

← 1 2 3 4 5 →